Announcement on Election of Employee Director
Filed with SSE · · 2 pages · Chinese
Dizal (Jiangsu) Pharmaceutical Co. Ltd. on 6ix
Earlier from Dizal (Jiangsu) Pharmaceutical
- Announcement on Vesting Results in the 2nd Vesting Period for Category I Incentive Objects of Those Initially Granted in the 2022 Restricted Stock Incentive Plan and Stock Listing
- Announcement on Voluntary Disclosure of Information Regarding Multiple Studies on Golidocitinib (Gaoruize) and Birelentinib Included in the 67th Annual Meeting of the American Society of Clinical Hematology (ASH)
- Announcement on Initial Public Offering of Temporarily Idle Raised Funds for Cash Management
- Announcement on Convening the Q3 2025 Performance Briefing
- Announcement on Circulation of Restricted Shares Issued to Specific Objects
Later from Dizal (Jiangsu) Pharmaceutical
- Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025
- Announcement on Listing and Circulation of Shares from the 1st Exercise Window of the 2nd Exercise Period under the 2020 Employee Stock Option Plan
- Announcement on Changing Registered Capital, Amending the Articles of Association, and Handling Industrial and Commercial Change Registration
- Announcement on the Resignation of Independent Directors
- Announcement on Resolutions of the 18th Meeting of the 2nd Board of Directors
Follow Dizal (Jiangsu) Pharmaceutical into a list and get an email when it puts out news.
Follow Dizal (Jiangsu) Pharmaceutical